论文部分内容阅读
目的观察分析低剂量干扰素与利巴韦林结合治疗丙肝代偿期肝硬化的临床效果。方法将自2014年11月至2016年4月间在我院接受治疗的49例丙肝代偿期肝硬化患者为研究对象,按自愿原则将患者分组并采用不同药物进行治疗,并在治疗后对观察指标进行统计评价。结果采用低剂量干扰素与利巴韦林结合治疗的观察组的HCV-RNA阴性转化率为84%优于采用利巴韦林治疗的对照组的66.67%,P<0.05;观察组的治疗总有效率为88%显著优于对照组的70.83%,P<0.05;均有统计学意义。结论采用低剂量干扰素与利巴韦林结合治疗丙肝代偿期肝硬化可获得较好的HCV-RNA阴性转化率,且疗效显著。体会对丙肝代偿期肝硬化采用低剂量干扰素与利巴韦林结合为一种较为理想的用药方式,可在临床上加以推广应用。
Objective To observe and analyze the clinical effect of combining low-dose interferon with ribavirin in the treatment of decompensated cirrhosis of liver. Methods From November 2014 to April 2016 in our hospital for treatment of 49 cases of hepatitis C decompensated cirrhosis patients as the object of study, according to the voluntary principle, the patients were grouped and treated with different drugs, and after treatment of Observed indicators for statistical evaluation. Results The negative conversion rate of HCV-RNA in the observation group treated with combination of low-dose interferon and ribavirin was 84.6% higher than that in the control group treated with ribavirin, P <0.05; the total treatment of the observation group Efficacy of 88% was significantly better than the control group of 70.83%, P <0.05; all were statistically significant. Conclusions The combination of low-dose interferon and ribavirin in the treatment of hepatitis C decompensated cirrhosis can obtain better HCV-RNA negative conversion rate, and the curative effect is remarkable. Experience of hepatitis C decompensated cirrhosis with low-dose interferon and ribavirin combined as a more ideal way of medication, can be clinically promoted.